STOCK TITAN

Immunogen Inc - IMGN STOCK NEWS

Welcome to our dedicated page for Immunogen news (Ticker: IMGN), a resource for investors and traders seeking the latest updates and insights on Immunogen stock.

Immunogen Inc (IMGN) is a clinical-stage biotechnology leader pioneering targeted cancer therapies through its proprietary antibody-drug conjugate (ADC) technology. This dedicated news hub provides investors and industry professionals with timely updates on IMGN's scientific advancements, regulatory milestones, and strategic partnerships.

Our curated collection offers immediate access to official press releases, clinical trial developments, and collaboration announcements. Users will find updates on oncology research progress, FDA interactions, and technology licensing agreements that shape IMGN's position in the biopharmaceutical landscape.

Key content types include pipeline advancements for solid tumor treatments, partnership expansions with major pharmaceutical companies, and financial disclosures. The platform serves as a reliable resource for understanding how IMGN's ADC platform addresses complex oncology challenges through precision-targeted therapeutics.

Bookmark this page for streamlined tracking of IMGN's scientific and corporate developments. Combine these updates with Stock Titan's analysis tools to monitor the company's progress in transforming cancer treatment paradigms.

Rhea-AI Summary
ImmunoGen, Inc. has announced the approval of grants of non-qualified stock options and restricted stock units (RSUs) under the Inducement Equity Incentive Plan to a new employee. The options have exercise prices of $14.86 per share and will vest over time based on the employee's continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
none
-
Rhea-AI Summary
ImmunoGen's Marketing Authorization Application for mirvetuximab soravtansine accepted by the EMA for the treatment of platinum-resistant ovarian cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary
ImmunoGen Inc. to host conference call to discuss third quarter 2023 operating results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
Rhea-AI Summary
ImmunoGen approves grants of stock options and RSUs to new employees under the Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
none
-
Rhea-AI Summary
ImmunoGen Inc. announces findings from Phase 3 trial of ELAHERE in patients with FRα-positive platinum-resistant ovarian cancer, showing improvements in progression-free survival, objective response rates, and overall survival compared to chemotherapy. The benefit seen with ELAHERE in patients treated with a prior PARP inhibitor is particularly encouraging. ELAHERE demonstrates a tolerable safety profile. The company plans to submit applications to regulatory authorities for approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
none
-
Rhea-AI Summary
ImmunoGen grants non-qualified stock options and restricted stock units to new CFO Lauren White
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
none
Rhea-AI Summary
ImmunoGen appoints Lauren White as Senior Vice President and Chief Financial Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
management
-
Rhea-AI Summary
ImmunoGen, Inc. approves grants of stock options and RSUs to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Summary
ImmunoGen enters exclusive collaboration with Takeda to develop and commercialize ELAHERE in Japan, receiving $34 million upfront and milestone payments, as well as double-digit royalties on future net sales in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.92%
Tags
none
Immunogen Inc

Nasdaq:IMGN

IMGN Rankings

IMGN Stock Data

8.72B
278.38M
0.32%
86.52%
7.38%
Biotechnology
Healthcare
Link
United States
Waltham